Synthesis and bio-evaluation of newer dihydropyridines and tetrahydropyridines based glycomimetic azasugars.

Autor: Deswal N; Bio-organic Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India., Takkar P; Bio-organic Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India., Kaur L; Department of Radiological, Nuclear and Imaging Science, Institute of Nuclear Medicine and Allied Sciences, Defence Research Development and Organization, Delhi 110054, India., Ojha H; Department of Radiological, Nuclear and Imaging Science, Institute of Nuclear Medicine and Allied Sciences, Defence Research Development and Organization, Delhi 110054, India., Kumar R; Bio-organic Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India. Electronic address: rakeshkp@email.com.
Jazyk: angličtina
Zdroj: Bioorganic chemistry [Bioorg Chem] 2024 Apr; Vol. 145, pp. 107224. Date of Electronic Publication: 2024 Feb 18.
DOI: 10.1016/j.bioorg.2024.107224
Abstrakt: This study presents the synthesis and bio-evaluation of new triazolylated dihydropyridine and tetrahydropyridine azasugar scaffolds (F1-14). Azasugar glycomimetics are the synthetic substances that mimic the structural and functional characteristics of natural carbohydrates showcasing promising potential as therapeutic agents for diabetes. The α-glucosidase inhibitory activity of synthesized final compounds were evaluated against the commercially available α-glucosidase enzyme. Majority of the screened compounds displayed excellent inhibition with IC 50 values ranging from 2.12 to 75.11 μM, when compared to the standard drug Acarbose. Particularly, compound F5 with IC 50 value of 2.12 μM was found to be the most active compound among the series. Further molecular docking studies of selected ligands were performed to investigate the binding interactions with enzyme active sites. Their specific binding patterns have been analysed with the binding sites of Saccharomyces cerevisiae α-glucosidase. These findings suggest these candidates as the potential leads for the anti-diabetic activity.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: